Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Ribomic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Ribomic"},{"company":"Ribomic","sponsor":"AJU Pharma","pharmaFlowCategory":"D","amount":"$6.0 million ","upfrontCash":"Undisclosed","newsHeadline":"RIBOMIC Enters License Agreement with AJU Pharma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Ribomic"},{"company":"Santen Pharmaceutical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen, Tracon discontinue development of eye drug after mid-stage trial failure","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Santen Pharmaceutical"},{"company":"Ribomic","sponsor":"Midwest Eye Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RIBOMIC Inc. Provides Update on RBM-007 Program in Wet Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Ribomic"}]

Ribomic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

RIBOMIC Inc. Provides Update on RBM-007 Program in Wet Age-Related Macular Degeneration

Details:

Further analysis of Phase 2 TOFU data and results from the RAMEN study in previously treated wAMD show no benefit of RBM-007, a novel oligonucleotide-based aptamer with potent anti-FGF2 activity, monotherapy or the combination over Eylea in any of the study outcome measures.

Lead Product(s): RBM-007

Therapeutic Area: Ophthalmology Product Name: RBM-007

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Midwest Eye Institute

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 23, 2022

ASK
US

Upload
your Pipeline Activity

Ribomic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

RIBOMIC Enters License Agreement with AJU Pharma

Details:

Upon execution of this Agreement, AJU will obtain the exclusive license to develop and sell the Product containing RBM-007 (the “Product”) in the Territory.

Lead Product(s): RBM-007

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: AJU Pharma

Deal Size: $6.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 17, 2020

ASK
US

Upload
your Pipeline Activity

Santen Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Santen, Tracon discontinue development of eye drug after mid-stage trial failure

Details:

The companies said DE-122, when combined with Lucentis, did not meet the trial's main goal of improving visual acuity in patients with wet AMD compared to those taking Lucentis alone.

Lead Product(s): Carotuximab

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 10, 2020

ASK
US

Upload
your Pipeline Activity

Ribomic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study)

Details:

First patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States.

Lead Product(s): RBM-007,Aflibercept

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 19, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY